Immunic Inc (IMUX) Stock Analysis

Immunic Inc (IMUX) is a publicly traded company in the HEALTHCARE sector. It trades at $15.13, carries a market capitalization of $206.09M. This page summarizes the public market data, fundamentals, and frequently asked questions for IMUX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $15.13
• Market Cap: $206.09M
• EPS: $-4.77
• 52-Week High: $15.77
• 52-Week Low: $5.06

Market Sentiment

Immunic Inc currently has a Bullish sentiment score of 0.43.

About Immunic Inc

Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company based in New York, specializing in the development of innovative oral immunology therapies for chronic autoimmune and inflammatory diseases. With a focus on addressing significant unmet medical needs, Immunic leverages its proprietary drug development platform to advance a robust pipeline of candidates currently in clinical trials. The company's commitment to enhancing patient outcomes positions it strategically within the bio...

GNG Research Analysis

GNG Research scores Immunic Inc (IMUX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IMUX.

Frequently Asked Questions

Does IMUX pay dividends?

Immunic Inc (IMUX) does not currently pay a regular dividend.

What is IMUX's market cap?

Immunic Inc (IMUX) has a market capitalization of $206.09M with a current stock price of $15.13.